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Abstract 
Background: Pax6 is a key regulator of the entire cascade of ocular lens formation through specific binding to 
promoters and enhancers of batteries of target genes. The promoters and enhancers communicate with each other 
through DNA looping mediated by multiple protein–DNA and protein–protein interactions and are marked by spe‑
cific combinations of histone posttranslational modifications (PTMs). Enhancers are distinguished from bulk chroma‑
tin by specific modifications of core histone H3, including H3K4me1 and H3K27ac, while promoters show increased 
H3K4me3 PTM. Previous studies have shown the presence of Pax6 in as much as 1/8 of lens‑specific enhancers but 
a much smaller fraction of tissue‑specific promoters. Although Pax6 is known to interact with EP300/p300 histone 
acetyltransferase responsible for generation of H3K27ac, a potential link between Pax6 and histone H3K4 methylation 
remains to be established.
Results: Here we show that Pax6 co‑purifies with H3K4 methyltransferase activity in lens cell nuclear extracts. Prot‑
eomic studies show that Pax6 immunoprecipitates with Set1a, Mll1, and Mll2 enzymes, and their associated proteins, 
i.e., Wdr5, Rbbp5, Ash2l, and Dpy30. ChIP‑seq studies using chromatin prepared from mouse lens and cultured lens 
cells demonstrate that Pax6‑bound regions are mostly enriched with H3K4me2 and H3K4me1 in enhancers and 
promoters, though H3K4me3 marks only Pax6‑containing promoters. The shRNA‑mediated knockdown of Pax6 
revealed down‑regulation of a set of direct target genes, including Cap2, Farp1, Pax6, Plekha1, Prox1, Tshz2, and Zfp536. 
Pax6 knockdown was accompanied by reduced H3K4me1 at enhancers and H3K4me3 at promoters, with little or no 
changes of the H3K4me2 modifications. These changes were prominent in Plekha1, a gene regulated by Pax6 in both 
lens and retinal pigmented epithelium.
Conclusions: Our study supports a general model of Pax6‑mediated recruitment of histone methyltransferases Mll1 
and Mll2 to lens chromatin, especially at distal enhancers. Genome‑wide data in lens show that Pax6 binding corre‑
lates with H3K4me2, consistent with the idea that H3K4me2 PTMs correlate with the binding of transcription factors. 
Importantly, partial reduction of Pax6 induces prominent changes in local H3K4me1 and H3K4me3 modification. 
Together, these data open the field to mechanistic studies of Pax6, Mll1, Mll2, and H3K4me1/2/3 dynamics at distal 
enhancers and promoters of developmentally controlled genes.
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Background
Cellular differentiation is regulated by a combinatorial 
action of sequence-specific DNA-binding transcription 
factors and extracellular signaling that results in activa-
tion and repression of specific batteries of genes [1–3]. 
These transcription factors detect regulatory sequences 
in promoters and enhancers, proximal and distal regu-
latory regions, respectively. These regulatory elements 
communicate together through DNA looping [4–6]. 
Transcriptionally active genes are marked by “open” chro-
matin domains accessible to nuclease digestions, specific 
combinations of core histone posttranslational modifi-
cations (PTMs), and incorporation of H2A.Z, H3.3 core 
histone variants into promoter regions [7–9]. In contrast, 
transcriptionally inactive genes are organized within 
compact chromatin domains, formation of which is pro-
moted by different sets of core histone modifications. 
Recent studies have provided novel insights into the 
structural and functional organization of these processes, 
including promoter–enhancer looping [3, 10], transcrip-
tion of enhancer-specific eRNA, and the use of ncRNAs 
in organizing transcriptional proteins [7, 11]. Neverthe-
less, the question of how DNA-binding transcription fac-
tors influence posttranslational modifications of histones 
and regulate transcription remains unanswered.
Genome-wide studies of chromatin by ChIP-seq 
have revealed that there is a relatively small number of 
core histone PTMs, including H3K4me1, H3K4me3, 
H3K27ac, and H3K27me3, which can be used as land-
marks for navigation through the chromatin landscape. 
Combinations of these PTMs in genomic regions have 
been shown to be highly associated with the locations 
of individual promoters and enhancers [12, 13]. Active 
promoter regions are occupied by DNA-binding tran-
scription factors and are highly enriched for H3K4me3 
and H3K27ac, while active enhancers are marked by a 
combination of H3K4me1 and H3K27ac. Another PTM, 
H3K4me2, decorates the majority of active promot-
ers and strong enhancers [13]. Furthermore, clusters 
of histone PTMs are associated with abundant histone-
modifying enzymes, including histone acetyltransferases 
(HATs) and methyltransferases (HMTs) [14, 15]. How 
these HATs and HMTs get to developmentally appropri-
ate promoters and enhancers is an open question. Of par-
ticular interest is the methylation status of H3K4 residues 
in histone H3N-terminal tails.
In mammalian cells, H3K4 methylations are catalyzed 
by a family of six distinct complexes. The Mll/Set1 com-
plexes contain enzymes with an evolutionarily conserved 
C-terminal catalytical SET domain and an evolutionarily 
conserved WRAD subcomplex (Wdr5, Rbbp5, Ash2l, and 
Dpy30). A few additional regulatory proteins discrimi-
nate between Mll and Set1 complexes [16]. For example, 
Set1a/b- and Mll1/2/3/4-containing complexes are dif-
ferent as the Set1 complexes contain additional Cfp1 
and Wdr82 subunits [17]. How mono- and dimethyla-
tion is “written” onto the fourth lysine of H3 tail differs 
from how trimethylation as the same residue is gener-
ated. H3K4 trimethylation results from promoter-specific 
H3K4me3 “indexing” during transcription. Specifically, 
the Wdr82 subunit of Set1a/b complexes binds to the 
phosphorylated C-terminal domain of RNA polymerase 
II at the initiation phase of transcription [18]. Alterna-
tively, the CpG-binding protein Cfp1 can recruit Set1a/b 
complex to the unmethylated CpG promoter regions [19]. 
Much less is known about the generation of H3K4 mono- 
and dimethylation. It is possible that the SET domain of 
these enzymes generates H3K4me1 and that the WRAD 
subcomplex possesses a “second” HMT activity, raising 
the possibility that the SET domain containing enzyme 
generates H3K4me1 and these substrates are dimethyl-
ated by the WRAD subcomplex, though the catalytical 
center of these activities remains unidentified [20].
Pax genes encode DNA-binding transcription fac-
tors that function as critical developmental regulators 
[21]. The Pax6 protein is composed of a bipartite DNA-
binding paired domain and an internal homeodomain. 
Together these domains bind to DNA and might serve 
as a surface for protein–protein interactions [22]. Pax6 
is a key regulator of eye morphogenesis [23, 24] and lens 
development [25–28]. Pax6 is also highly expressed in 
the dorsal part of the forebrain and has important func-
tions in neurogenesis and cortical patterning [29]. Pax-
6Sey/Sey mice are anophthalmic (i.e., lack the eyes) and 
display a range of abnormalities in other organs, includ-
ing the brain, olfactory system, and pancreas [30]. The 
homozygous deletion of Pax6 in the prospective lens 
ectoderm blocks lens induction [31]. The heterozygous 
Pax6+/− lens placodes are composed of reduced cell 
numbers [32] and subsequently develop into lenses of 
reduced size with subtle structural abnormalities [27, 
28, 30]. Interestingly, simultaneous deletion of CBP and 
p300 HATs in the prospective lens ectoderm phenocop-
ies defects found in Pax6 null ectoderm [33]. This pheno-
copying provides a mechanistic link between early roles 
of Pax6, acetylation of H3K18 and H3K27, and chromatin 
remodeling during embryogenesis [33]. Genetic stud-
ies of Pax6 have revealed a multitude of functions dur-
ing mouse embryonic development [27, 34], including 
roles as a dual transcriptional activator and repressor [35, 
36]. Pax6-mediated gene regulation is dosage sensitive; 
Pax6Sey/+ mice are viable, they have smaller and devel-
opmentally defective eyes [37], and their transcriptome 
is moderately disrupted [33, 38]. Gene reporter assays 
have also shown that Pax6 has concentration-dependent 
modes of transcriptional activation and repression [39]. 
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Unlike genetic studies of Pax6 in lens [31, 32, 40–42] and 
its DNA-binding activities [35, 43, 44], the understanding 
of Pax6-interacting proteins is in its infancy [22].
In the present study, we aimed to extend the under-
standing of the molecular mechanisms of Pax6-mediated 
gene activation and repression [45] by identifying chro-
matin remodeling activities associated with Pax6. Using 
an in  vitro assay, we detected a histone H3K4 HMT 
activity enriched in Pax6-specific immunoprecipitates. 
Subsequent proteomic studies identified Mll1, Mll2, and 
Set1a in these materials. ChIP-seq data revealed that 
Pax6 co-localized with H3K4me1/2 in distal enhancers 
and H3K4me1/2/3 in proximal promoters. Reduction 
of Pax6 expression in cultured lens cells identified hun-
dreds of differentially expressed genes, including seven 
positively regulated Pax6-direct targets (Cap2, Farp1, 
Pax6, Plekha1, Prox1, Tshz2, and Zfp536). Partial reduc-
tion of Pax6 expression resulted in reduced abundance of 
H3K4me1 in distal enhancers and of H3K4me3 in pro-
moter regions at the genome-wide level.
Results
Pax6 is associated with H3K4 methylation activity
To test our hypothesis that transcriptional regulation by 
Pax6 involves the regulation of histone methylation, we 
first immunoprecipitated Pax6 proteins from nuclear 
extracts of mouse lens epithelial cells (αTN4). We used 
Pax6-specific antibodies and tested the enriched pro-
teins by in  vitro HMT assay performed in the pres-
ence of labeled [3H] S-adenosyl methionine as methyl 
group donor and recombinant histone octamers as the 
substrates. We found that Pax6-, but not control IgG-
immunoprecipitates, were associated with HMT activ-
ity (Fig.  1a). To distinguish between the histones H3 
and H2B that closely migrate on the SDS-PAGE, we 
performed additional HMT assays using the individual 
recombinant H3 and H2B histones. We found that meth-
ylation was specific for histone H3 (Fig. 1b). To identify 
the potential methylation site and distinguish the methyl-
ation status of H3, we conducted an in vitro HMT radio-
metric filter assay using H3N-terminal peptides (residues 
1–20) with an unmodified, mono-, di-, or trimethylated 
lysine 4 (i.e., H3K4, H3K4me1, H3K4me2, and H3K4me3 
histone tail mimics). Pax6-containing immunoprecipi-
tates catalyzed methylations of these four peptides as 
various levels. We found comparable methylation effi-
ciencies between unmethylated and monomethylated 
peptides (Fig.  1c). In contrast, the HMT activity was 
reduced when dimethylated histone tail mimics were 
used, and the lowest incorporation of the methyl donor 
group was detected with the trimethylated peptides. We 
next evaluated Wdr5-containing immunoprecipitates 
and found that the HMT activities were much higher 
(Fig.  1d), most likely as Wdr5 is a common subunit of 
multiple Mll/Set1 complexes. These data suggest that this 
reconstituted in  vitro methylation Pax6-containing sys-
tem possesses the ability to modify monomethylated sub-
strates and that the system can utilize H3K4me1 peptide 
mimics for additional methylations and raise the possibil-
ity that Mll/Set1 complexes may be present in Pax6-con-
taining immunoprecipitates.
Pax6‑immunoprecipitates from lens nuclear extracts 
contain Set1a, Mll1, and Mll2
Mammalian genomes encode at least six different protein 
complexes that are known to methylate H3K4 residues. 
To identify the H3K4 methylase and other proteins asso-
ciated with Pax6, we employed a non-biased proteomic 
approach. By immunoprecipitating with Pax6 antibod-
ies, we purified “Pax6 complexes” and used liquid chro-
matography-tandem mass spectrometry (LC–MS/MS) to 
identify Pax6-associated proteins in the nuclear extract 
prepared from αTN4 cultured lens epithelial cells. In 
total, we identified 301 protein clusters with a high confi-
dence score as described in “Methods” (Additional file 1: 
Table S1). The majority of the identified proteins belong 
to the functional groups of chromatin modifiers, chro-
matin remodelers, RNA processing, or DNA-binding 
proteins (Additional file  1: Table S1). Importantly, the 
chromatin modifiers identified include Mll1, Mll2, and 
Set1a enzymes and their associated proteins (Fig.  2a). 
Other notable chromatin modifiers and remodelers 
include ISWI, SWI/SNF, NuRD complexes, p300, and 
CBP HATs (Fig.  2b). It was previously shown that Pax6 
interacts with p300 in cell extracts of cultured pancre-
atic α-cells [46], ATP-dependent catalytical subunit of 
SWI/SNF complexes Brg1 (Smarca4) in extracts from 
mouse adult neural stem cells, and BAF170 (Smarcc2) 
in mouse cerebral cortex [47, 48]. In addition, the Brg1/
Pax6 complexes were detected in co-transfected 293T 
cells [49]. Immunoprecipitations using Mll1, Mll2, and 
Set1a antibodies revealed the presence of Pax6 proteins 
(Fig. 2c). We further identified all common Mll complex 
subunits, i.e., Wdr5, Rbbp5, Ash2l, and Dpy30, by inde-
pendent co-IPs followed by western blots (Fig.  2c). In 
addition, we validated the presence of both subunits of 
the histone chaperone complex FACT, Ssrp and Spt16 
[50], which remodels nucleosomal structure to facilitate 
RNA polymerase II movement through nucleosomes 
(Fig.  2d). Finally, we found that fragments of Snf2h 
(Smarca5), and its three regulatory subunits Rsf1, Wstf, 
and Acf1 (Fig. 2b), forming the binary RSF1, WICH, and 
ACF chromatin remodeling complexes, respectively [51], 
were highly abundant in Pax6-immunoprecipitates. The 
presence of Snf2h in Pax6-immunoprecipitates was also 
validated by co-IP westerns (Fig.  2e). Consistent with 
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the role of Pax6 in transcriptional repression [35, 36], all 
components of the histone deacetylase-containing NuRD 
complexes [52] were also found (Fig.  2b). It is worth 
noting that two abundant lens nuclear proteins, menin-
binding protein Psip1 (alternate names: LEDGF, p75) 
[53] and Ncoa6 (alternate names: AIB3, ASC2, RAP250, 
Trbp) [54], were not found (Additional file 1: Table S1). 
Both Psip1 and Ncoa6 are substoichiometric subunits of 
Mll1/2 and Mll3/4 complexes [17], respectively. Taken 
together, these proteomic studies coupled with in  vitro 
methyltransferase assays support the idea that Pax6-
Mll1, Pax6-Mll2, and Pax6-Set1a complexes exist in lens 
cell nuclear extracts.
Distribution of histone PTMs at promoters and enhancers 
in lens chromatin
The biochemical association between Pax6 and enzymes 
that catalyze the methylation of H3K4 residues prompted 
us to examine the distribution of H3K4me1, H3K4me2, 
and H3K4me3 in regions of lens chromatin occupied by 
Pax6. Previously, we had mapped H3K4me1, H3K4me3, 
H3K27ac, H3K4me3, and RNA polymerase II in newborn 
lens chromatin [45]. Here we also analyzed the locali-
zation of H3K4me2 at 222 Pax6-bound promoters and 
proximal to 3501 non-promoter Pax6-containing peaks 
(Fig. 3). In the promoters (Fig. 3a), the normalized signal 
intensities for H3K4me2 around Pax6-bound sites were 
higher compared to H3K4me3 and H3K27ac levels. The 
“peaks” in the H3K4me2 and H3K4me3 profiles were 
shifted from the Pax6 summits, while reduced nucleoso-
mal density was indicated by small valleys near the Pax6 
peaks (Fig. 3a). In contrast, in the non-promoter regions 
the profiles for H3K4me1, H3K4me2, and H3K27ac were 
symmetrical around the Pax6-binding sites, but also 
showed a reduction at the center of Pax6 peaks (Fig. 3b). 
By computing the correlation of Pax6 and H3K4me1/2/3 
ChIP-seq read densities across Pax6-binding sites (±5 kb 
of Pax6 peak summits), we found that Pax6 occupancy 
was significantly correlated with H3K4me in both 
promoters and distal regions. The Pearson’s correla-
tion coefficients (r) for the promoter Pax6 peaks were 
0.30 (p  =  3.8e-6) for H3K4me1, 0.31 (p  =  1.96e-6) for 
H3K4me2, and 0.24 (p = 2.5e-4) for H3K4me3, while the 
coefficients were 0.38 (p = 4.73e-15), 0.26 (p = 2.64e-55), 
a
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Fig. 1 Pax6‑immunoprecipitates contain histone methyltransferase activities specific for recombinant histone H3. a In vitro HMT assay using recom‑
binant histone octamers. The Pax6‑immunoprecipitates were used at 1x (+) and 2x (++) amounts. Input represents the lens cell nuclear extract. 
IgG‑immunoprecipitates were used as a control. b In vitro HMT assay using recombinant H2A and H3 histones. IgG‑immunoprecipitates were used 
as a control. c In vitro HMT assay using unmodified, mono‑, di‑ and trimethylated H3K4 peptides (residues 1–20) in the presence of Pax6‑immuno‑
precipitates. d In vitro HMT assay using unmodified, mono‑, di‑ and trimethylated H3K4 peptides in the presence of Wdr5‑immunoprecipitates. The 
HMT activities of control IgG‑immunoprecipitates were subtracted in both c, d. (error bars = ±s.d.)
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and 0.11 (p  =  1.17e-10) for the non-promoter Pax6 
peaks, respectively. Together with the data shown in 
Fig.  3, these quantification analyses indicate that Pax6 
occupancy shows the largest correlation with H3K4me1 
enrichment but also agree with previous genome-wide 
studies implicating H3K4me2 as a marker of tissue-spe-
cific gene regulation [55] and transcription factor binding 
regions [56].
Identification of Pax6 sites in cultured lens epithelial cells
To gain mechanistic insight into Pax6 binding and 
H3K4 methylations, we established a cell culture sys-
tem suited to the down-regulation of Pax6. We analyzed 
Pax6 binding in αTN4 lens cells used in biochemical 
studies described above by ChIP-seq and found 502 
peak regions. We identified 245 of them as being com-







































Fig. 2 Identification of individual protein components in Pax6‑containing immunoprecipitates. a Subunit structure of Mll1/2 and Set1a complexes 
and number of specific peptides (n) of these subunits identified by LC–MS/MS. b Pax6‑immunoprecipitates contain additional subunits of multiple 
chromatin‑modifying and remodeling complexes, including BAF, ACF, RCF, WICH, NuRD, NuA4, HAT, and HMT. The catalytical subunits of these com‑
plexes are shown in green. c Co‑IP validation of Pax6 in immunoprecipitates obtained using Mll1, Mll2, Set1a, Wdr5, Rbbp5, Cfp1, Ash2l, and Dpy30 
antibodies. d Co‑IP validation of the FACT complex subunits Ssrp and Spt16 in Pax6‑immunoprecipitates. e Co‑IP validation of the Snf2h (Smarca5) 
in Pax6‑immunoprecipitates. IgG‑immunoprecipitates were used as control. Protein markers are shown in kDa
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To demonstrate the specificity of these peaks, we found 
significant enrichment of Pax6 consensus motifs within 
these Pax6 peaks (Fig. 4b) [35, 43, 45]. It is worth noting 
that we found additional common cis-motifs enriched 
at Pax6-bound promoters and enhancers, including Ets, 
Meis, and AP-1 (Fos-Jun)-binding sites (Fig. 4c). Individ-
ual members of these families of transcription factors, 
including c-Jun, Etv5, Meis1, and Meis2, regulate lens 
development [25].
We next determined the distribution of H3K4me1, 
H3K4me2, and H3K4me3 in αTN4 lens chromatin. Based 
on Pax6 ChIP-seq data (Fig. 4a), we separated Pax6 peaks 
into lens-specific (n  =  3478), αTN4/lens “common” 
(n  =  245) peaks, and αTN4-specific peaks (n  =  257) 
Lens Pax6 promoter Peaks (n=222)
Pax6  Pol2 K4me1 K4me2 K4me3 K27ac K27me3
Lens Pax6 non promoter Peaks (n=3501)












































Distance to Pax6 peak summits
a b
Fig. 3 Lens Pax6 promoter and non promoter peaks show different histone modification patterns in mouse lens chromatin. a Pax6 promoter peaks 
are co‑localized with H3K4me2, H3K4me3 and H3K27ac in mouse lens chromatin. b Lens Pax6 non‑promoter peaks are co‑localized with H3K4me1, 
H3K4me2, and H3K27ac. The heatmap shows read densities in 50‑bp bins from ±5 kb of the Pax6 peak summits. Pax6, RNA polymerase II, H3K4me1, 
H3K4me2, H3K4me3, H3K27ac, H3K27me3 ChIP‑seq data in lens tissue are shown. The lower panels show mean ChIP‑seq read densities from −5 to 
+5 kb around Pax6 peak summits. The rows in the heatmaps were sorted by the Pax6 signals (likewise in Figs. 5, 7).
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(Fig.  5). Interestingly, we found that lens-specific and 
αTN4-specific Pax6 peaks showed a greater enrichment 
of H3K4me1/2 in the specific cell types where Pax6 bind-
ing was detected (Fig.  5a,c), whereas “common” Pax6 
peaks displayed similar H3K4me1/2 enrichment in both 
cell types (Fig.  5b). These results further support the 
conclusion from Fig.  3 that Pax6 binding is highly cor-
related with H3K4me1 and H3K4me2, i.e., enhancer 
regions. These studies also indicate that Pax6-direct 
target genes in αTN4 cells may function as models to 
probe the relationship between Pax6 binding and H3K4 
methylations. 
Pax6 knockdown and gene expression changes
To test the link between Pax6 and methylation of 
H3K4, we used shRNA-mediated Pax6 knockdown 
(KD) in αTN4 cells to identify genes regulated by Pax6. 
To achieve this goal, we established two independ-
ent stable Pax6 KD αTN4 cell lines with two differ-
ent shRNA constructs. The knockdown efficiency was 
a b
c
Fig. 4 Pax6‑binding site analysis and identification of enriched motifs around Pax6 peak summits. a 502 Pax6 peaks were identified in αTN4 chro‑
matin, including 245 shared with the newborn mouse lens chromatin. b 502 Pax6 peaks identified in αTN4 chromatin are enriched with Pax6 motifs 
similar to those identified from 3723 Pax6 peaks in lens chromatin and by in vitro DNA‑binding studies. c Additional motifs assigned to Ets, Meis, 
and AP‑1 families of transcription factors were also identified at the Pax6 peaks. The regions examined are defined as ±100 bp under the Pax6 peak 
summits
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examined by qRT-PCR and immunoblotting. There was 
an 80 % reduction of Pax6 mRNA and protein levels in 
the Pax6 sh2 line, but only a 60 % reduction in the Pax6 
sh1 line (Fig. 6a). Neither of these engineered cell lines 
displayed any obvious defects in morphology or growth 
rate.
To find which genes were affected by reduced Pax6 lev-
els, we performed RNA analysis in both control and Pax6 
Lens specific Pax6 Peaks (n=3478)
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Fig. 5 Lens‑specific and common Pax6 peaks of mouse lens chromatins show similar histone modification patterns. a Lens‑specific Pax6 peaks 
are co‑localized with H3K4me1, and H3K4me2 in mouse lens tissue. Heatmap shows read density in 50‑bp bins from −5 to +5 kb of the peak 
summits at lens‑specific Pax6 peaks (n = 3478). b Common Pax6 peaks are co‑localized with H3K4me1, and H3K4me2 in both lens tissue and αTN4 
cells. Heatmap shows read density in 50‑bp bins from −5 to +5 kb of the peak summits at Pax6 common peaks between lens tissue and αTN4 
cells (n = 245). c αTN4 specific Pax6 peaks are co‑localized with H3K4me1, and H3K4me2 in αTN4 cells. The right panel shows mean ChIP‑seq read 
density for all ChIP‑seq data from −5 to +5 kb around Pax6 peak summits
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sh1 cells to identify differentially expressed genes that 
were sensitive to Pax6 reduction. We pooled two biologi-
cal replicates each and performed a comparative analysis 
by RNA-seq. In total, we found 131 genes significantly 
differentially expressed in sh1 Pax6 KD cells, including 
68 up- and 63 down-regulated transcripts. Among these 
genes, a group of seven genes, including Cap2, Farp1, 
Pax6, Plekha1, Prox1, Tshz2, and Zfp536, were both 
bound by Pax6 and differentially expressed in both Pax6 
sh1 and sh2 cells (Fig. 6b). We next evaluated expression 
of these genes using qRT-PCR (Fig.  6c). Expression of 
Cap2, Pax6, Plekha1, Tshz2, and Zfp536 transcripts was 
also significantly reduced in Pax6 KD cells (p  =  0.001 
by Fisher’s exact test, Fig.  6c). In contrast, three genes, 
including Csf1, Dhrs3, and Eya4, were up-regulated as a 
result of Pax6 depletion. It is worth noting that Prox1 and 
Pax6 have already been shown to be direct Pax6 targets 
in newborn lens [45].
Reduction of Pax6 expression changes levels of H3K4me3 
in promoters and H3K4me1 in distal regions
To test how reduced expression of Pax6 influences 
H3K4 methylation, we conducted ChIP-seq studies of 
H3K4me1, H3K4me2, and H3K4me3 in control and Pax6 
KD sh2 αTN4 cells (Fig.  7). No Pax6 peaks were called 
from the Pax6 KD cells by our analysis (data not shown), 
so we analyzed all Pax6 peaks in the control αTN4 cells. 
In the promoters (n  =  34, with corresponding pol2 
enrichment), we found a strong reduction in H3K4me3 
and a weak reduction in H3K4me1 signals but no changes 
in H3K4me2 (Fig. 7a). In the distal non-promoter regions 
(n =  468), the major difference was reduced H3K4me1 
abundance (Fig.  7b). To evaluate the statistical signifi-
cance of H3K4me1 reduction in non-promoter Pax6 
peaks that may function as enhancers, we decided to ana-
lyze the changes of H3K4me1/2/3 read densities between 






Fig. 6 Analysis of gene expression in Pax6 shRNA lens cell lines. a Knockdown of Pax6 by lentivirus shRNA (sh1 and sh2). Upper panel qRT‑PCR. 
Lower panel western immunoblot. b Overlap of Pax6‑bound genes and differentially expressed genes. Differentially expressed genes were detected 
by RNA‑seq. c qRT‑PCR validation of Pax6 positively regulated genes: Cap2, Farp1, Pax6 (see a), Plekha1, Prox1, Tshz2, and Zfp536. p values <0.05 by 
Student’s t tests are labeled as *, while p values <0.01 were labeled as **
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were identified as H3K4me1 peaks in the WT chromatin. 
As evaluating by a Mann–Whitney U statistical test, we 
found that the reduction of H3K4me1 in the Pax6-bound 
enhancers was statistically significantly higher than that 
in the enhancers without Pax6 binding (p  =  2.53e-11), 
while the changes of H3K4me2/3 were not significant 
(Fig.  7c), indicating that H3K4me1 reduction at distal 
enhancers is related to reduced Pax6 occupancy in Pax6 
KD αTN4 cells. Similarly, we also compared promoters 




Fig. 7 Disruption of histone methylation patterns around Pax6 peaks in Pax6 KD cell line sh2. a αTN4 Pax6 promoter peaks (n = 34) showed 
decreased H3K4me1 and H3K4me3 modification but no change of H3K4me2 in Pax6 KD cell line (vs wt). Pol2 data are also shown to indicate pro‑
moters. b Non‑promoter αTN4 Pax6 peaks showed decreased H3K4me1 modification in Pax6 KD cell line (n = 468). Heatmaps show read densities 
from ±5 kb of the Pax6 peak summits, sorted by the Pax6 ChIP‑seq signal in WT, with the profiles of mean ChIP‑seq read densities plotted in the 
right (top for WT and bottom for shPax6 data). c Changes (wt vs Pax6 KD) of H3K4me1/2/3 at two groups of enhancers (used WT H3K4me1 peaks as 
a proxy here) separated by their overlap with Pax6 peaks. Upon Pax6 KD, the enhancers with Pax6 binding showed a greater reduction of H3K4me1 
(but no change in H3K4me2/3) than those without Pax6 binding in WT. The boxplots show RPKM (reads per kb peak per million ChIP‑seq reads) dif‑
ferences between control and Pax6 KD αTN4 cells; the RPKMs were computed for at ±5 kb of the centers of H3K4me1 peaks
Page 11 of 18Sun et al. Epigenetics & Chromatin  (2016) 9:37 
marked reduction of H3K4me3 in the promoters (Fig. 7a) 
was not statistically significant (p = 0.30), which may be 
due to the small numbers of promoters bound by Pax6 
(n = 34).
Plekha1 is regulated by Pax6 in mouse αTN4 and RPE cells
To illustrate the connections between Pax6 and 
H3K4me1 and H3K4me3, we focused on pleckstrin 
homology domain containing, family A (phosphoi-
nositide binding specific) member 1, Plekha1. The human 
PLEKHA1-ARMS2-HTRA1 gene cluster is on chromo-
some 10; GWAS studies have implicated this cluster in 
the pathogenesis of age-related macular degeneration 
(AMD) [57], a disease caused by dysfunctional retinal 
pigmented epithelium (RPE). Differentiation of RPE cells 
is regulated by the transcription factors Pax6, Otx2, and 
Mitf [58]. Recent studies have shown that Otx2 [59, 60] 
regulates Plekha1 expression during mouse ES cell differ-
entiation [61] and that binding of Otx2 was found in the 
Plekha1 gene in the adult mouse neuroretina [62].
In the mouse Plekha1 locus two Pax6-containing 
peaks were identified in the evolutionarily conserved 
5′-distal region ~27-kb upstream (region A) and in the 
third intron (region B) in control αTN4 cell chromatin 
(Fig.  8a). Two predicted Pax6-binding sites as well as 
accompanying Maf- and Sox-binding sites in region A are 
shown in Additional file 2: Fig. S2. Importantly, region A 
is marked by abundant H3K4me1 and H3K4me2 as well 
as RNA polymerase II suggesting a putative enhancer. 
In Pax6 KD αTN4 cells, both H3K4me1 and H3K4me2 
signals around region A are reduced and accompanied 
by reduced abundance of H3K4me3 in the Plekha1 pro-
moter (Fig. 8a).
To gain additional insights into Plekha1 gene expres-
sion, we determined its expression in the mouse embry-
onic eye (stages E13.5, E15.5, and E19.5). We found 
Plekha1 proteins showed nuclear expression throughout 
the eye, most notably in the corneal epithelium, lens, and 
neuroretina (Fig. 8b). Finally, in order to examine the sig-
nificance of Pax6’s regulation of Plekha1 outside of the 
lens, we tested this system in the RPE. E15.5 RPE from 
mice with tissue-specific Pax6 depletion [58] were ana-
lyzed by qRT-PCR and demonstrated reduction of Ple-
kha1 transcript level (Fig. 8c). Taken together, these data 
identify Plekha1 as a novel dosage-sensitive direct target 
of Pax6 in lens and RPE cells.
Discussion
Sequence-specific DNA-binding transcription factors 
regulate gene expression by controlling the activity of 
enhancer regions. What molecular mechanisms are used 
for this regulation is a major unanswered question in the 
field of gene regulation and embryonic development. It 
has been proposed that the recruitment of chromatin 
remodeling enzymes/complexes by DNA-binding factors 
elicits local changes in chromatin structure that either 
promote or inhibit gene expression. A combination of 
genetic and functional studies has shown that a sparse 
number of transcription factors, including FoxA1, Gata1, 
HNF4α, MyoD, Mitf, Nrl, PU.1, Pax5/BSAP, Pax6, Runx2, 
and Sox9, function as molecular switches to control cell-
fate decision steps. Within this group, Pax6 functions 
during the earliest stages of eye development in both 
ectoderm- and neuroectoderm-derived progenitor cells 
and regulates many subsequent steps of eye morphogen-
esis. As Pax6 functions as a dual transcriptional activator 
and repressor [25], we reasoned that an unbiased iden-
tification of its associated proteins and enzymatic activi-
ties toward core histone proteins would provide novel 
insights into mechanisms of Pax6-mediated gene con-
trol during embryonic development. The positively act-
ing chromatin remodeling complexes/enzymes identified 
here include Mll1, Mll2, and Set1a HMT complexes and 
CBP and EP300 HATs. The identification of the NuRD 
complex in Pax6-immunoprecipitates may explain how 
Pax6 functions as a transcriptional repressor. The dual 
role of Pax6 in activation and repression could be also 
mediated through recruitment of SWI/SNF and ISWI 
chromatin remodeling complexes [47–49]. We have 
shown earlier that CBP and p300, Brg1 (Smarca4), and 
Snf2 h (Smarca5) regulate lens induction [33] and differ-
entiation [63, 64].
The interactions between Pax6 and Mll/Set1 com-
plexes are further supported by our findings that Pax6-
containing immunoprecipitates contain important 
regulatory subunits such as the WRAD subcomplex and 
catalyze in  vitro methylation of H3 core histones and 
H3-derived histone tail mimetics. Although the meth-
ylation reactions are markedly reduced when H3K4me3 
substrates are used with Pax6-immunoprecipitates, the 
“residual” activity detected raises the possibility that the 
other lysine or arginine residues present are also meth-
ylated in this system, though direct proof remains to be 
obtained.
To gain insights into Pax6-dependent histone PTMs, 
we studied the landscapes of H3K4 methylation in three 
systems: newborn lens and control and Pax6 KD αTN4 
lens cells. The analysis of lens chromatin identified a pre-
ferred association between Pax6 binding and H3K4me2. 
Nevertheless, upon Pax6 KD expression, the abundance 
of distal H3K4me1 and promoter H3K4me3 modifica-
tion, but not H3K4me2 modification, was reduced at 
a genome-wide scale. These data imply that Pax6 may 
recruit Mll1 and Mll2 to the distal regions and Set1a to 
the promoters. These protein recruitments could cata-
lyze H3K4me1 and H3K4me2 modifications and generate 
Page 12 of 18Sun et al. Epigenetics & Chromatin  (2016) 9:37 
H3K4me3 residues. Although the Set1a/b complexes 
bind to the phosphorylated C-terminal domain of RNA 
polymerase II via the Wdr82 subunit at the initiation 
phase of transcription, our data suggest that Pax6 may 
also recruit a fraction of the Set1a complex to the pro-
moter prior the onset of transcription. Additional stud-
ies will be needed to determine the localizations of Mll1, 
Mll2, and Set1a enzymes in lens chromatin (by ChIP-seq 
when antibodies are available and/or by engineering the 
αTN4 to insert in frame epitope tags into genes encoding 
the Mll/Set1a-specific subunits). At the level of individual 
genes, we document changes at Plekha1’s distal enhancer. 
In addition, we show that Pax6 regulates Plekha1 in RPE 
cells and we establish for the first time its expression 
domains in the mouse embryonic eyes.
Although ten genes with disrupted regulation were 
found in the present Pax6 KD αTN4 system, it is impor-
tant to stress that the reduction of Pax6 expression was in 
the range of inactivating one functional Pax6 copy (hap-
loinsufficiency) and this reduction in vivo generates only 
subtle defects in the lens. We restrained ourselves from 
reducing the Pax6 protein to ~10–15 % of normal levels, 
as we were concerned that the engineered αTN4 cells 
would lose their cell-type identity.
To better understand our Pax6 KD system, we consid-
ered a few “indirect” possibilities: that depletion of Pax6 
a
b c
Fig. 8 Regulation of Plekha1 gene expression by Pax6. a Reduced Pax6 binding affects H3K4me1 and H3K4me3 patterns at Plekha1 enhancer 
and promoter regions. Pax6, H3K4me1, H3K4me2, H3K4me3, and Pol II ChIP‑seq signal at Plekha1 locus in cultured lens cell chromatin. The mouse 
Plekha1 locus is shown including the portion of the downstream Htra1 gene. The evolutionary conservation (upper track‑green color) and predicted 
Pax6‑binding sites A (see Fig. S2 for details) and B are indicated. b Expression of Plekha1 proteins in mouse embryonic eye. Note that in the lens 
transitional zone and other cell types, Plekha1 (red) is found in the nuclei (DAPI stainings, blue). Scale bar is 100 µm. c qRT‑PCR expression of Plekha1 
in the mouse E15.5 RPE of control Pax6loxP/loxP and mutant Pax6loxP/loxP; DctCre demonstrated a fold change of 0.81 (pV = 0.005, n = 3). Spearman’s 
correlation between Pax6 and Plekha1 is 0.76 (pV = 0.037, n = 3)
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could affect expression of subunits comprising the Mll/
Set1 complexes, or that Pax6 could be “globally” involved 
in controlling the levels of H3K4 methylations. To test 
the first possibility, we examined the protein levels of 
Ash2l and Rbbp5 in both control sh and Pax6 sh2 cells 
by immunoblotting. We normalized the protein levels to 
TATA-box-binding protein (TBP) and did not find any 
global changes (Additional file  2: Fig. S1a). To examine 
whether there were any cellular H3K4me changes in Pax6 
KD cells, we compared the H3K4 methylation levels from 
the whole cell lysates of control and Pax6 KD sh2 cells by 
immunoblotting. Individual H3K4me1, H3K4me2, and 
H3K4me3 signals were normalized to TBP, and no nota-
ble changes were found (Additional file 2: Fig. S1b), indi-
cating that a reduction of Pax6 expression did not affect 
the net cellular activity of H3K4 methylases. We con-
cluded that reduction of Pax6 expression does not affect 
expression of two common WRAD subunits and global 
levels of methylated histones.
The molecular mechanisms underlying the genesis of 
tissue-specific enhancers, the significance of individual 
and combined histone PTMs, and the “writing” order 
and “reading” recognition of histone PTMs, remain 
poorly understood, especially in the context of develop-
mentally regulated genes. Enhancers can be viewed as 
highly organized chromatin domains primarily organ-
ized by sequence-specific transcription factors. During 
and/or following their formation, the distal enhancer 
domains physically contact the promoter-bound pro-
tein–DNA complexes, and promoter–enhancer loops are 
established to facilitate efficient recruitment of the basal 
transcriptional machinery [10]. The birth of enhancers 
is thought to involve recruitment of multiple chromatin 
remodeling systems by the “pioneering” transcription 
factors [65, 66]. The “net” effect of these DNA–protein–
protein interactions is the generation of enhancer-spe-
cific patterns of core histone PTMs, including H3K4me1 
and H3K27ac [13, 67] and the establishment of “open” 
chromatin/nucleosome-free regions [66, 68, 69]. Pax6 
functions as a highly selective molecular switch that acti-
vates gene expression in different cell types and represses 
those same genes in other cell types [25]. Our earlier 
studies have shown that Pax6 binds 2/3 of common sites 
in two distinct lens and forebrain chromatins [45]. This 
finding raises the possibility that Pax6 functions as a pio-
neering factor. Previous studies have shown that Pax6 
binds with p300 HAT [46] and SWI/SNF complexes via 
direct binding to Brg1, Brm, Baf155, and Baf170 [47–49]. 
The present data add Mll1, Mll2, and Set1a to the list 
of Pax6-associated chromatin-modifying enzymes and 
suggest a number of additional novel chromatin remod-
eling complexes are linked to Pax6, such as ACF, RSF, 
WICH, and NuRD, which explain the dual roles of Pax6 
as transcriptional activator and repressor (Fig. 9). Taken 
together, Pax6 possesses many activities attributed to 
pioneering factors; nevertheless, additional studies are 
needed to find whether Pax6 can access its target sites in 
chromatin independently on other DNA-binding tran-
scription factors.
At present, few DNA-binding transcription factors 
are known to bind Mll-containing HMT complexes. The 
Pax2, Pax3, and Pax7 factors have been shown to bind 
Mll3/4 complexes via the adaptor protein PTIP [70] 
or through distinct adaptor protein Pax3/7BP (official 
name: Paxbp1) [71]. Recently, the developmental regula-
tors MafA [72], Oct4 [73], Pitx2 [7], and Tbx1 [75] have 
also been shown to interact with specific Mll complexes. 
Neither PTIP nor Paxbp1 was detected among the 301 
Pax6-interacting clusters. We propose that the common 
property of multiple Pax transcription factors is to direct 
recruitment of Mll HMT complexes.
The most common partners of Pax6 in tissue-specific 
gene control in lens include bZIP protein c-Maf, nuclear 
receptor complex RARβ/RXRβ, and HMG-box Sox2 [39, 
76] and are all known to bind p300 and CBP HATs [77]. 
Thus, the “master” role of Pax6 in embryonic develop-
ment can be explained in molecular terms by its ability 
to recruit a full complement of positively acting chroma-
tin remodelers (e.g., HATs, HMTs, and ATP-dependent 
remodelers) and to provide additional service through 
recruitment Mll1 and Mll2, which methylate the enhanc-
ers. Future studies will be aimed to test these Pax6 
protein–protein interactions and their role in enhancer-
mediated tissue-specific gene control.
Conclusions
This study reveals interactions of Pax6 with multiple 
chromatin-modifying and remodeling complexes and 
supports a general model of Pax6-mediated recruit-
ment of histone methyltransferases Mll1 and Mll2 at 
distal enhancers in lens chromatin. Although genome-
wide data in lens show that Pax6 binding correlates with 
H3K4me2, consistent with the idea that H3K4me2 PTMs 
correlate with the binding of transcription factors, reduc-
tion of Pax6 by shRNA expression induces prominent 
changes in local H3K4me1 and H3K4me3 modifications. 
These findings open the field to mechanistic studies of 
Pax6, Mll1, Mll2, and dynamics of H3K4 methylations at 
distal enhancers and promoters of developmentally con-
trolled genes in lens and other tissues regulated by Pax6, 
including forebrain, retina, and pancreas.
Methods
Antibodies
Ash2l (Bethyl, A300-489A), Cfp1 (Abcam ab198977), 
Dpy30 (Bethyl A304-296A), H3K4me1 (Abcam, ab8895), 
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H3K4me2 (Abcam, ab7766), H3K4me3 (Abcam, ab8580), 
H3K9me2 (Abcam, ab1220), H3K79me2 (Abcam, 
ab3594), IgG (Millipore 12-370), Mll1 (Bethyl A300-
086A), Mll2 (Santa Cruz, H300, sc-292359), Pax6 (Mil-
lipore, ab2237), Plekha1 (Novus, NBP1-86967), Rbbp5 
(Bethyl, A300-109A), RNA polymerase II (Santa Cruz, 
N-20), Set1a (Bethyl, A300-289A), Snf2h (Active Motif, 
39543), Spt16 (Biolegend, 607001), Ssrp (Biolegend 
609702), TBP (Abcam, ab51841), vinculin (Abcam, 
ab129002), and Wdr5 (Bethyl A302-429A) were used.
Immunoprecipitation analysis
Mouse lens epithelial cell line αTN4 was used for immu-
noprecipitation assays. All procedures were done at 4 °C. 
Nuclear extracts were prepared as described [78]. Protein 
G Dynabeads (Invitrogen) were used for immunopre-
cipitation. The beads were block with 1 % BSA before the 
day of immunoprecipitation. On the day of immunopre-
cipitation, nuclear extracts were dialyzed into the BC200 
(20  mM HEPES, pH 7.9, 0.2  mM EDTA, 0.5  mM DTT, 
20 % glycerol, 0.2 % NP-40, and 200 mM KCl) buffer. For 
antibody conjugation, 5 µg of Pax6, Wdr5, or control IgG 
antibodies was incubated with Dynabeads for at least 6 h. 
For nuclear extract pre-cleaning, 200 µg nuclear extracts 
were diluted with BC200 to 200  ng/µl and incubated 
with Dynabeads for 2  h. Pre-cleaned nuclear extracts 
were incubated with antibody-conjugated Dynabeads for 
overnight. The beads were washed twice with BC200 and 
twice with BC500. Finally, the beads were resuspended in 
30 µl BC200 and used for subsequent assays.
Mass spectrometry
Samples processed for LC–MS/MS were subjected to 
SDS-PAGE and silver stained as described previously [79]. 
Bands were excised and analyzed on a LTQ linear ion trap 
mass spectrometer (ThermoFisher Scientific, Waltham, 
MA) interfaced with a Rapid Separation LC 3000 system 
(ThermoFisher Scientific) and a TriVersa NanoMate system 
(Advion, Ithaca, NY). Mgf files were created from the raw 
LTQ mass spectrometer LC–MS/MS data using Proteome 
Discoverer 1.3 (ThermoFisher Scientific). The created mgf 
files were used to search the NCBI database using the in-
house Mascot Protein Search engine version 2.4.1 (Matrix 
Science) with the following parameters: trypsin 2 missed 
cleavages; fixed modification of carbamidomethylation 


































Fig. 9 A general model of enhancer‑dependent transcriptional activation by Pax6 through recruitment of chromatin‑modifying and remodeling 
complexes. The present data coupled with earlier studies on Pax6 suggest a general model that explains chromatin features near Pax6‑bound peaks. 
The Pax6/Brg1‑ and Pax6/Snf2h‑containing ATP chromatin remodeling complexes are initially assembled in the enhancer and promoter regions. 
Pax6 is then joined by additional DNA‑binding factors (not shown). In subsequent stages, enhancer‑bound Pax6 recruits Mll1/2 complexes and 
the region is marked by H3K4me1 and H3K4me2, followed by recruitment of p300, and generation of H3K27ac. Similarly, at the promoter regions, 
binding of Pax6 facilitates recruitment of cooperating DNA‑binding factors (shown: Maf and Sox2), followed by various chromatin‑modifying and 
remodeling activities, and formation of physical contacts between these assemblies mediated by DNA looping. As the transcription commences, 
Set1a traveling with the RNA polymerase will convert the unmodified and partially methylated H3K4 residues into the high density of H3K4me3
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pyro-glu (Glu and Gln), and oxidation (Met); monoisotopic 
masses; peptide mass tolerance of 2 Da; product ion mass 
tolerance of 0.6 Da. The final list of identified proteins was 
generated by Scaffold 4.0.5 (Proteome Software, Portland, 
OR) with the following conditions: 99 % minimum protein 
probability, minimum number of 3 unique peptides, and 
95 % peptide probability.
HMT assay
Pax6 or control IgG antibody precipitates from nuclear 
extract as described above were incubated with 1  µg 
recombinant histones in the presence of [3H] S-adenosyl-
l-methionine (SAM), for 1 h at 30 °C. The following pro-
cedure is done as we described earlier [80].
Radiometric filter methyltransferase assay
N-terminal H3 peptides (1–20) containing unmodified 
K4, K4me1, K4me2, and K4me3 residues were obtained 
from Epicypher (catalog #: 12-0001, 12-0007, 12-0008, 
and 12-0009). The reactions (20  µl, final volume) were 
conducted with 1  µg of the peptide, specific immuno-
precipitate (Pax6, Wdr5, and IgG control), [3H] SAM 
(0.55  µCi/µl, PerkinElmer), and BC200 buffer. After 1-h 
incubation at 30  °C, the reaction mixture was spotted 
on P81 phosphocellulose paper (Millipore) and washed 
3× with sodium carbonate, pH 8.5 and 1× with acetone 
before air-drying. Four milliliters of scintillation cock-
tail was added to the filter paper, and emissions were 
counted. CPM were normalized to IgG control.
Cell cultures and generation of shRNA cell lines
αTN4 cells are SV40 T-antigen-transformed mouse lens 
epithelial cells [81] that express many important lens-
specific genes [82] and were maintained in DMEM F-12 
with 10 % FBS. Lentiviral constructs expressing shRNAs 
including the controls were purchased from OpenBiosys-
tems (Pax6 sh1: 5′-CCACTTCAACAGGACTCATTT-3′, 
Pax6 sh2: GCAAGAATACAGGTATGGTTT, and control 
sh: 5′-CTCGCTTGGGCGAGAGTAA-3′). Viral particles 
were produced by following the recommended protocols 
(Addgene). Two days after infection of cells with viruses, 
puromycin was added at 2  mg/ml to select for pooled 
populations of stably infected cells.
ChIP‑seq assays and peak calling
Ten 20-cm dishes of control and Pax6 sh2 αTN4 cells were 
cross-linked with 1 % formaldehyde at room temperature 
for 10 min and quenched by 2.5 M glycine. The ChIP was 
performed using antibodies as we described elsewhere [45]. 
Sequencing of Pax6 and histone ChIP-seq experiments 
was performed on Illumina HiSeq 2500 and Genome Ana-
lyzer IIx instruments. The ChIP-seq reads were analyzed 
by the Einstein WASP analysis pipeline [83] and aligned 
to the mouse genome (GRCm37/mm9) using Bowtie [84]. 
The data were deposited into GEO under accession num-
bers GSE66961 and GSE76315. For Pax6, RNA polymer-
ase and histone modifications (H3K4me2 and H3K4me3) 
with sharp ChIP-seq profiles, peaks were called using the 
MACS2 program [85] using default settings. For histone 
modifications with broad ChIP-seq profiles (H3K4me1), 
peaks were called using the SICER program using default 
setting [86]. We filtered out peaks that mapped to the 
modENCODE blacklisted genomic regions [87]. The IGV 
Integrative Genomics Viewer (2.3.57) [88] was used for 
data visualization. Pax6 peaks overlapping at least 1  bp 
between lens and αTN4 cells are assigned as common 
peaks (n = 245) and others as specific peaks by BEDTools 
(v2.23.0) [89]. The peak overlap between the two cell types 
is significant (p < 2.2e-16 by Fisher’s exact test).
Unbiased motif analysis at Pax6‑bound regions
MEME (4.10.1) [90] and MEME-ChIP [91] were used to 
identify de novo enriched motifs with sequences −100 to 
+100  bp around Pax6 peak summits in lens and αTN4 
cells; the setting was 6–20 bps as motif width and return-
ing the top 10 motifs.
Identification of Pax6 peaks association to genes and data 
visualization
The list of TSSs (transcription start sites) list was down-
loaded from the UCSC genome browser [92] using the 
RefSeq gene annotations [93]. Pax6 peaks overlapping 
at least 1  bp with the −2 to +2  kb around TSS were 
assigned as Pax6 peaks using the BEDTools (v2.23.0). The 
rest were considered as non-promoter peaks and further 
assigned to genes if they were within 50 kb of a gene as 
described previously [45]. The heatmaps to visualize his-
tone modification were generated by Java Treeview [94] 
using the count matrix generated by the SeqMINER pro-
gram [95], counting the read densities from −5 to +5 kb 
around Pax6 peak summits in 50  bp bins. During this 
analysis, the same numbers of ChIP-seq reads (~16 mil-
lions) were used, with a subset sampled from the full data 
set that had >16 million reads.
qRT‑PCR and RNA‑seq experiments
Total RNA was extracted from αTN4 cells on a 6-well plate 
using TRIzol reagent and reverse-transcribed using the 
SuperScript III First-Strand Synthesis System (Invitrogen). 
Relative mRNA levels were normalized against average 
of Gapdh and B2  m. The library construction, sequenc-
ing, and data analysis were performed as we described 
previously [45]. The following primer pairs were used: 
B2m, 5′-CATACGCCTGCAGAGTTAAGC-3′, 5′-GA 
TGCTTGATCACATGTCTCG-3′; Cap2, 5′-GGAAG 
CAACATGTTCAACCA-3′, 5′-CGTCGTTCATCTCCT 
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TGACA-3′; Farp1, 5′-CCAGGGAAGGTTCTGTTTGA-3′, 
5′-ACCACGATCTTCCTGTGGTC-3′; Gapdh, 5′-CTT 
CCGTGTTCCTACCC-3′, 5′-TGCTGTAGCCGTATTCA 
T-3′; Pax6, 5′-GCACATGCAAACACACATGA-3′, 5′-AC 
TTGGACGGGAACTGACAC-3′; Plekha1, 5′-GACAG 
AATCGCATCTGTGGA-3′, 5′-TGAAGGCAGGTTCTG 
TGGAT-3′; Prox1, 5′-TGACTCGGGACACAACAAGT-3′, 
5′-ATCTCTCTGGAACTGCGCTT-3′; Tshz2, 5′-GCGG 
CAAGAATGATTTTGAT-3′, 5′-ATAGCTGCACGGAG 
CTGAAT-3′; and Zfp536, 5′-CAATGGGCAGAACCTA 
GGAA-3′, 5′-ATGCTATTGAACCGGAAACG-3′.
Analysis of conditionally inactivated Pax6 in RPE cells
The mouse lines employed in this study, Pax6loxP [31] 
and DctCre [96], have been previously described. The 
genetic background of all mice used in this study was 
C57BL/6J. All animal work was conducted according to 
national and international guidelines and approved by 
the Tel Aviv University Review Board. For RNA isola-
tion, RPEs of control Pax6loxP/loxP and mutated Pax6loxP/
loxP; DctCre mice were dissected at E15.5 and RNA was 
extracted using QIAshredder and RNeasy kits (Qiagen). 
Reverse transcription of 1  µg of RNA from each sam-
ple was performed using qScript cDNA Synthesis Kit 
(Quanta). cDNA was amplified using the Power SYBR 
Green Mix (Applied Biosystems) in a 384-well optical 
reaction plate using ABI Prism 7000 Sequence Detection 
System (Applied Biosystems).  Plekha1 primers used for 
qRT-PCR are described above, and relative expression 
was normalized using Tbp and Hprt transcripts. Immu-
nofluorescence analysis was performed on 10-µm paraf-
fin sections as previously described [96] using primary 
rabbit anti-Plekha1 antibody and secondary antibody of 
donkey anti-rabbit conjugated to Alexa 594 (1:1000, Inv-
itrogen, A21207).
Additional files
Additional file 1: Table S1. Complete list of Pax6 associated proteins 
identified by MS
Additional file 2: Fig. S1. Semi‑quantitative analysis of Ash2 l and Rbbp5 
expression and global histone methylation in Pax6 KD cells. a Western 
immunoblotting to show that Pax6 KD does not impair expression levels 
of common subunits, Ash2 l and Rbbp5. Expression of basal transcrip‑
tion factor TBP was used as loading control. b Western immunoblotting 
to show that Pax6 KD does not affect methylation levels of histone H3, 
including H3K4m1, H3K4me2, H3K4me3, H3K79me2 and H3K9me2. Fig. 
S2. Transcription factor binding sites in the evolutionarily conserved 
distal region of Plekha1. Two Pax6 binding sites were identified within the 
Pax6 ChIP‑seq peak (Fig. 8a, region A). In addition, analysis of surround‑
ing sequences predicts two Sox‑ and one large Maf‑binding sites. The 
Sox‑ and Maf‑binding motifs are from JASPAR database (Sox motif ID: 
15863505; Maf motif ID: 9571165). The Pax6 motif is based on ChIP‑seq 
studies in αTN4 cells (see Fig. 4b).
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